` ETX (E-Therapeutics PLC) vs FTSE All Share Index Comparison - Alpha Spread

ETX
vs
F
FTSE All Share Index

Over the past 12 months, ETX has underperformed FTSE All Share Index, delivering a return of 0% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
ETX vs FTSE All Share Index

Loading
ETX
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ETX vs FTSE All Share Index

Performance Gap Between ETX and ASX
HIDDEN
Show

Performance By Year
ETX vs FTSE All Share Index

Loading
ETX
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
E-Therapeutics PLC vs Peers

FTSE All Share Index
ETX
RYI
GLDD
AVGR
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

E-Therapeutics PLC
Glance View

Market Cap
52.6m GBX
Industry
Biotechnology

e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company is headquartered in Witney, Oxfordshire and currently employs 18 full-time employees. The company went IPO on 2007-11-28. The firm's platform is a combination of databases and a suite of computational tools that employ network analysis, data mining, machine learning, artificial intelligence (Al) and optimization. Its in silico platform serves as a laboratory, which enables it to computationally test potential therapeutic interventions. Its network-driven drug discovery (NDD) technology performs computational phenotypic screens to identify efficacious drugs. Its genome-associated interactions networks (GAINs) technology interprets genomic data in the context of the biological networks, in which the genes function. Its ribonucleic acid (RNA) Interference, (RNAi) platform is in development to complement its computational toolset. The firm identifies new therapeutic approaches to modulate a specific mechanism involved in Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic indications through Galapagos NV (Galapagos).

ETX Intrinsic Value
Not Available
Back to Top